Composition having antitumor effect

Details Composition having antitumor effect Composition having antitumor effect

2011-01-18

2011-01-18

Chen, Stacy B (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S007230

Reexamination Certificate

active

07871765

ABSTRACT:
The present invention is intended to provide a pharmaceutical composition for delivering a chemotherapeutic, preferably an anticancer drug, into cells or into a living organism, using a viral envelope vector, and provides a pharmaceutical composition comprising a chemotherapeutic encapsulated in, or used in combination with, a viral envelope vector having an adjuvanticity as an active ingredient. Thereby it is possible to introduce an anticancer drug encapsulated in a viral envelope vector directly into a tumor, with coadministration of another anticancer drug so as to induce tumor cell-specific antitumor immunity also thanks to the adjuvant action of HVJ-E, and hence to regress the tumor. The present invention also provides a pharmaceutical composition comprising a viral envelope vector and a chemotherapeutic as active ingredients.

REFERENCES:
patent: 1170363 (2002-01-01), None
patent: 1420065 (2004-05-01), None
patent: 1447451 (2004-08-01), None
patent: 2001-286282 (2001-10-01), None
patent: 2001-302541 (2001-10-01), None
patent: 2002-065278 (2002-03-01), None
patent: WO 94/21798 (1994-09-01), None
patent: WO 98/50071 (1998-11-01), None
Tsuyoshi Nakanishi et al., “Antigen-delivery system for CTL vaccine”, Drug Delivery System, 1999, vol. 14, No. 6, pp. 459 to 469.
Palmer, J. C. et al., Non-infectious virus induces cytotoxic T Lymphocytes and binds to target cells to permit their lysis, Nature, 1977, vol. 269, pp. 595 to 597.
Fukami, Y. et al., Difference in Capacity of Sendai Virus Envelope Components to Induce Cytotoxic T Lymphocytes in Primary and Secondary Immune Responses, Infection and Immunity, 1979, vol. 26, No. 3, pp. 815 to 821.
Fujihara et al., “Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation,”Cancer Immunol. Immunother. 57, 73-84, 2008.
Kawaguchi et al., “Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle,”Int. J. Cancer 124, 2478-87, 2009.
Kurooka & Kaneda, “Inactivated Sendai Virus Particles Eradicate Tumors by Inducing Immune Responses through Blocking Regulatory T Cells,”Cancer Res 67, 227-236, 2007.

Affiliated with

Also associated with

Rating

Composition having antitumor effect does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition having antitumor effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition having antitumor effect will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2687244